Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
News18 English
News18 » India
1-min read

PPI Antacids under Scanner for Kidney Failure Side Effect, Need to Carry Warning from Now

The US FDA has also recommended that these drugs, often available as over-the-counter antacids, should be taken on specific indications and for not more than eight weeks.

Sneha Mordani | CNN-News18

Updated:November 6, 2019, 6:35 PM IST
facebookTwitter Pocket whatsapp
PPI Antacids under Scanner for Kidney Failure Side Effect, Need to Carry Warning from Now
Representative image.

New Delhi: The Drugs Controller General of India has asked the Central Drugs Standard Control Organisation (CDSCO) to ask state drug controllers to direct manufactures of formulations of Proton Pump Inhibitors (PPI) to mention ‘acute kidney injury’ as an adverse drug reaction in the package of these medicines.

Simply put, these medicines, often available as over-the-counter antacids, will have to carry the ‘adverse kidney injury’ warning from now.

This is a significant step towards patient safety. The US FDA has also recommended that these drugs should be taken on specific indications and for not more than eight weeks.

Antacids are taken to suppress acids in the stomach. However, there is a tendency for indiscriminate use as a result of which a patient often gets addicted to the drug.

The advisory came after the National Coordination Centre Pharmacovigilance Program of India raised concerns. A note that was forwarded in the form of a recommendation based on adverse drug reaction (ADR) reports on certain medical products, including Proton Pump Inhibitors, were discussed.

The objective was to signal information leaflet change from Indian data and promote patient safety. Subsequently, the recommendations were deliberated upon at a meeting held on October 10 at CDSCO. The committee recommended the label warning and this has now been incorporated.

A study done by the American Medical Association, researchers at Yale and John Hopkins reviewed two groups of patients. Out of 10, 482 patients taking PPI, more than 50% were likely to suffer from chronic kidney disease. Taking two pills a day was linked to a 46% jump in risk for kidney diseases.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

Read full article
Next Story
Next Story

facebookTwitter Pocket whatsapp

Live TV

Countdown To Elections Results
To Assembly Elections 2018 Results